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Summary
 
Objective 
 
The introduction of ready-to-use lanreotide Autogel®
has presented the possibility of patients receiving their acromegaly
treatment at home. The objective of this study was to assess the ability
of patients (or their partners) to administer repeat, unsupervised,
injections of lanreotide Autogel without compromising efficacy or
safety.
 
Design 
 
Multicentre (10 UK regional endocrine centres), open-
label, nonrandomised, controlled study. Patients elected either to
receive/administer unsupervised home injections after injection
technique training (Test group) or continued to receive injections
from a healthcare professional (Control group). Patients received
monthly injections of lanreotide Autogel® at their established dose.
Effects were monitored for up to 40 weeks.
 
Patients 
 
Thirty patients (15 per treatment group) with acromegaly
treated with a stable dose of lanreotide Autogel® (60, 90 or 120 mg)
for 
 
≥
 
 4 months before screening.
 
Measurements 
 
The main outcome measure was the proportion of
patients/partners who successfully administered injections through-
out the study.
 
Results 
 
All Test group patients/partners qualified to administer
injections. Fourteen of 15 patients fulfilled all criteria for successful
administration of unsupervised injections (95% confidence inter-
val, 70%–99%). Fourteen of 15 Test and 14/15 Control patients
maintained growth hormone and IGF-1 control. Local injection
tolerability was good for both treatment groups, and safety profiles
were similar. All Test group patients continued with unsupervised
injections after the study.
 
Conclusions 
 
Patients with acromegaly or their partners were able
to administer lanreotide Autogel® injections with no detrimental
effect on efficacy and safety; therefore, unsupervised home injections
are a viable alternative to healthcare professional injections for
suitably motivated patients.
(Received 8 June 2007; returned for revision 22 June 2007; finally 
 
revised 24 July 2007; accepted 5 August 2007)
 
Introduction
 
The introduction of somatostatin analogues was a major therapeutic
advance in the management of acromegaly. Slow-release, long-acting
formulations, administered by fortnightly or monthly injections,
have been found to control plasma GH levels, normalize serum
levels of IGF-1 and reduce clinical symptoms in over 50% of patients.
 
1
 
Lanreotide Autogel® (Ipsen Pharma Biotech SAS, Signes, France)
is a long-acting viscous aqueous formulation of lanreotide, which is
supplied in ready-to-use prefilled syringes intended for deep sub-
cutaneous injection. Lanreotide Autogel® provides consistent
drug release and is effective in controlling the biochemical markers
and symptoms of acromegaly when injected every 28 days
 
1–8
 
. Lan-
reotide Autogel® does not require reconstitution, a process which
can be problematic and cause administration problems due to
needle blockage by microparticles.
The availability of a ready-to-use preparation has raised the
possibility of home administration by the patient or a trusted relative
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or friend (partner). This could be beneficial to patients in reducing
the impact of the disease on their daily lives and also in improving
acceptability of long-term therapy. In addition, if lanreotide Autogel®
can be safely administered unsupervised, while maintaining disease
control, this would reduce the clinic time required by these patients.
The aim of this study was to assess whether patients with
acromegaly could successfully self-administer, or receive from their
partners, monthly injections of lanreotide Autogel® without any loss
of clinical efficacy or deterioration in the safety profile.
 
Patients and methods
 
Prior to patient enrolment, the study was approved by the London
Multicentre Research Ethics Committee and the Local Research Ethics
Committee for each study centre. It was conducted in accordance
with the Declaration of Helsinki and the International Conference
on Harmonization – Good Clinical Practice. All patients, and their
partners if applicable, gave written informed consent before entering
the study.
 
Patients
 
Thirty patients aged 18 years or older with a clinical diagnosis of
acromegaly were to be included in this study. All patients must have
been treated with a stable dose of lanreotide Autogel (60, 90 or
120 mg per month) for at least 4 months before entering the study.
Study patients were required to have a mean serum GH level
 
≤
 
 10·0 
 
μ
 
g/l within 4 weeks of the Baseline visit, and a life expectancy
of at least 12 months at the time of screening. Patients were excluded
if they had undergone pituitary surgery within 6 months or radio-
therapy within 1 year of study screening, or if they were likely to
require either of these interventions during the study period. Other
exclusion criteria included ongoing treatment with a GH antagonist
or somatostatin analogue other than lanreotide Autogel.
 
Methods
 
This was a phase IV, multicentre, open-label, controlled study to
assess the ability of suitably motivated patients with acromegaly, or
their partners, to administer repeat injections of lanreotide Autogel
without supervision from a healthcare professional (defined as an
endocrinologist or endocrine nurse specialist).
Following screening (week –4) to assess patient eligibility, patients
chose whether to enter the Test or the Control group at the Baseline
visit (week 0). All patients were given a lanreotide Autogel injection
by a healthcare professional at the Screening and Baseline visits.
Control group patients continued to receive their lanreotide Autogel
injections every 4 weeks from a healthcare professional throughout
the study. After the Baseline visit, Control group patients received a
further nine injections (weeks 4–36). Test group patients either
administered the injections themselves or received their injections
from a ‘partner’. ‘Partner’ was defined as any person whom the
patient trusted and deemed responsible enough to administer their
injections. Having observed the healthcare professional demonstrate
the injection technique at Baseline, Test group patients (or their
partners) performed between one and three supervised training
injections at weeks 4, 8 and 12, as necessary. The ability of the
patient/partner to perform the injections was evaluated by a healthcare
professional after each supervised injection. Once the patients (or
partners) were considered qualified to administer unsupervised
injections, they were provided with supplies of study drug enabling
six subsequent unsupervised injections to be administered at home
once every 4 weeks.
All patients received lanreotide Autogel at the same dose they had
been receiving at the time of entry into the study. Lanreotide Autogel
was administered by deep subcutaneous injection into the upper
external quadrant of the buttock (for healthcare professional and
partner injections) or into the upper outer thigh (for self-injections).
The effects of treatment were monitored for a maximum of
40 weeks. Throughout the study, all patients were required to
complete diary cards to record information about injections admin-
istered, tolerability and safety.
 
Outcome measures
 
Mean GH, IGF-1 and drug (serum lanreotide) concentrations were
assessed at Baseline, Interim visit, and Study Completion. These
analyses were done using fasting samples collected before adminis-
tration of the study medication (i.e. at trough lanreotide levels).
Mean GH was calculated from between five and nine blood samples
taken at 30-min intervals over a 4-h period in the morning.
Interim visits were conducted at week 20 for Control group
patients and after three unsupervised injections for the Test group
(week 20, 24 or 28, depending on the number of training injections
required). Study Completion visits were conducted at week 40 for
Control group patients and after six unsupervised injections (week
32, 36 or 40) for the Test group.
The primary efficacy endpoint was the proportion of patients
(or partners) who successfully administered home injections of
lanreotide Autogel throughout the study, as assessed using the
following criteria:
• The patient (or partner) was declared qualified by a healthcare
professional to administer unsupervised injections after a maximum
of three training injections;
• The patient had received adequate treatment throughout the study as
assessed by the healthcare professional at the Study Completion visit;
• The patient’s disease control (assessed by evaluating plasma GH
and IGF-1 levels) was maintained.
Secondary endpoints included:
• The proportion of patients whose GH ‘control band’ (i.e. mean GH
either above or below an arbitrary level of 5 
 
μ
 
g/l) and whose age-
related IGF-1 level ‘control band’ (low/normal or elevated) at the
Interim and Study Completion visits was the same as or improved
from Baseline;
• The change in mean GH, IGF-1 and serum lanreotide levels from
Baseline to the Interim and Study Completion visits;
• Patient assessment of injection site tolerability;
• Patient (or partner) and healthcare professional evaluation of
unsupervised injections.
Safety measurements were made throughout the study and
included assessments of adverse events (AEs), clinical laboratory
tests, physical examinations and vital signs.
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Assay methods
 
All laboratory samples were analysed by a central laboratory.
 
GH
 
Serum GH levels were measured using an Immulite 1000 kit
(solid-phase, two-site chemiluminescent immunometric assay)
according to the manufacturer’s instructions. The assay has an
analytical sensitivity of up to 0·1 
 
μ
 
g/l and a broad working range of
0·2–40 
 
μ
 
g/l. Conversion: 
 
μ
 
g/l 
 
×
 
 2·6 
 
=
 
 mIU/l (WHO 1st IS 80/505).
 
IGF-1
 
Serum IGF-1 levels were measured using an Immulite 1000 kit
(solid-phase chemiluminescent immunometric assay) according to
the manufacturer’s instructions. The analytical sensitivity of the
assay is 0·02 
 
μ
 
g/l.
 
Drug concentration
 
Serum lanreotide levels were measured using a validated, in
house,  Ipsen radioimmunoassay method. The assay has a lower
detection limit of 0·078 
 
μ
 
g/l and an accepted working range of
0·078–0·480 
 
μ
 
g/l. The result of any sample was accepted if the co-
efficient of variation of the duplicate was < 15%.
 
Statistical methods
 
Given the exploratory nature of the study, no formal statistical
analysis was performed. Summary statistics were calculated for the
primary and secondary endpoints and reported with their two-sided
95% confidence intervals (CIs), calculated using the Wilson bino-
mial method. Efficacy analyses used the intention to treat population
(ITT; patients who received at least one dose of study medication
and who provided data for at least one efficacy variable) and the safety
analyses used the safety population (patients who received at least
one dose of study medication and who provided any follow-up data
for efficacy or safety variables). The primary endpoint was also assessed
using the per protocol (PP) population, which included all patients
who completed the trial in accordance with the study protocol.
 
Results
 
Patients studied
 
Thirty patients aged 29–86 years (43% female, 
 
n
 
 = 13) were enrolled,
received at least one dose of study medication and completed the
study (Test, 
 
n
 
 = 15; Control, 
 
n
 
 = 15). The baseline demographic
characteristics of the study population are summarized in Table 1.
Test group patients were younger than those in the Control group
(
 
P = 
 
0·0001) and were more likely to have undergone previous
pituitary surgery (
 
P < 
 
0·0001) and radiotherapy (not significant). The
mean length of prior treatment with lanreotide Autogel (
 
P =
 
 0·0092)
and other somatostatin analogues (not significant) was longer for
Control than Test patients.
Of the 15 Test group patients, 12 chose to self-administer and three
had their injections administered by their partner. All Test group
patients (or their partners) were declared qualified to administer
unsupervised injections after training; 14 patients required only one
injection training session and although the remaining patient was
considered by the healthcare professional to be qualified after the first
training session, the patient requested a further supervised injection.
In the Test group, five patients received the 60-mg dose of
lanreotide Autogel, five patients received the 90-mg dose and five
received the 120-mg dose. In the Control group, 10 patients received
the 60-mg dose, three patients received the 90-mg dose, and two
received the 120-mg dose.
There were three major protocol violations. In the Control group,
one patient missed the week 16 and week 24 injections, and therefore
the other visits were later than scheduled, and one patient missed
the week 16 injection, and therefore their Interim visit was early. In
the Test group, one patient administered an unscheduled seventh
unsupervised injection a day before the Study Completion visit,
which was therefore rescheduled for a month later. Patients with
major protocol violations were excluded from the PP population.
Table 1. Demographic and baseline characteristics
Variable
Control group 
(n = 15)
Test group 
(n = 15) P-value
Mean (SD) age, years 69·2 (8·1) 49·7 (14·0) 0·0001
Mean (SD) weight, kg 94·4 (19·9) 85·8 (14·8) NS
Gender
Male, n (%) 9 (60) 8 (53) NS
Female, n (%) 6 (40) 7 (47) NS
Mean (SD) time since diagnosis, months 116·8 (64·2) 109·4 (91·6) NS
Pituitary surgery, n (%) 4 (27) 14 (93) < 0·0001
Radiotherapy, n (%) 5 (33) 7 (47) NS
Mean (SD) length of treatment with lanreotide Autogel, months 29·7 (19·5) 13·9 (7·7) 0·0092
Mean (SD) length of treatment with other somatostatin analogue(s), months 64·4 (27·4) 55·5 (43·5) NS
SD, standard deviation; NS, not significant.
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Efficacy
 
Primary endpoint.
 
Fourteen of the 15 Test group patients (93%)
fulfilled all of the criteria for successful administration of unsuper-
vised injections (ITT population: 95% CI 70–99%; Table 2); the
results of the PP population supported this (93%; 95% CI 69–99%).
One patient did not meet the defined criteria for successful treatment
as their mean GH level increased from < 5 
 
μ
 
g/l at Baseline to > 5 
 
μ
 
g/l
at Study Completion (see footnote to Table 2). This patient had been
established on treatment with 60 mg lanreotide Autogel for
4 months before the study.
 
Secondary endpoints.
 
All patients in the Test and Control groups
maintained GH control (i.e. all patients were in the same or an
improved GH control band) at the Interim visit compared with Base-
line. Fourteen out of the 15 Test group patients (93%) and all 15
Control group patients maintained GH control at Study Completion
compared with Baseline (treatment difference Test 
 
vs.
 
 Control, –7%;
95% CI –30 to –14%; Table 2, Fig. 1). In one Test group patient, the
mean GH level increased from 2·0 
 
μ
 
g/l at Baseline to 6·7 
 
μ
 
g/l at Study
Completion (patient previously mentioned in connection with the
primary endpoint; Table 2, Fig. 2). For both treatment groups, there
were no notable changes in mean and median GH levels throughout
the study (Table 3, Fig. 1).
All 15 Test group patients and 14 out of 15 Control group patients
maintained IGF-1 control (i.e. were in the same or an improved IGF-
1 control band) at the Interim visit compared with Baseline. All Test
group patients and 14 out of 15 Control group patients maintained
IGF-1 control at Study Completion compared with Baseline (treatment
difference Test 
 
vs.
 
 Control, 7%; 95% CI –14 to –30%). One Control
group patient had worsened IGF-1 levels at the Interim visit (normal
to elevated), but this had returned to normal on Study Completion.
Another Control group patient moved from normal (181 
 
μ
 
g/l) to
elevated (241 
 
μ
 
g/l) on Study Completion (Table 3, Fig. 2). This
patient had been established on treatment with 60 mg lanreotide
Autogel 26 months before the study. For both treatment groups,
there was a decrease in mean (and median) IGF-1 levels from
Baseline to Study Completion. The decrease was more notable in the
Test group (Table 3, Fig. 1).
There were no notable changes in serum lanreotide concen-
trations in either the Test or Control group patients from Baseline
to the Interim and Study Completion visits (Table 3).
Local injection site tolerability was good for both treatment
groups with the majority of patients experiencing either none or only
mild pain, redness or swelling. Each patient’s perception of the pain
associated with the injection remained fairly constant throughout
the study. Within the Test group, the transfer to self- (or partner)
injections from those administered by a healthcare professional did
not affect the frequency or intensity of pain. There was a small
increase in the number of reports of mild redness or swelling during
the self- (or partner) administration period of the study, but these
were usually mild. The time taken to administer the injections was
comparable between treatment groups, mostly taking no more than
5 min to administer.
 
Safety
 
The most common AEs were gastrointestinal, for example, diarrhoea,
upper abdominal pain, nausea and constipation. No patients
Table 2. Overall outcomes
Criteria
Control group 
(n = 15) 
Number of 
patients (%)
Test group 
(n = 15) 
Number of 
patients (%)
Qualified after training N/A 15 (100)
Received adequate treatment 15 (100) 15 (100)
GH level maintained 15 (100) 14 (93)*
IGF-1 level maintained 14 (93)† 15 (100)
Overall treatment success N/A 14 (93)
N/A, not applicable.
*One patient (60-mg dose) had a GH level of 5·0 μg/l at Screening, 2·0 μg/l 
at Baseline, 3·3 μg/l at Interim assessment and 6·7 μg/l at Study Completion
†One patient (60-mg dose) had an IGF-1 level of 185 μg/l at Screening, 
181 μg/l at Baseline, 194 μg/l at Interim assessment and 241 μg/l at 
Completion.
Fig. 1 Median serum (and upper quartile) GH and IGF-1 levels throughout 
the study. GH, growth hormone; IGF-1, insulin-like growth factor-1.
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withdrew from the study because of AEs. There were no clinically
relevant changes or differences between treatment groups in any
clinical laboratory tests, vital signs or physical examination results.
 
Discussion
 
This study investigated whether patients with acromegaly could be
successfully trained to self-administer, or receive from a partner,
unsupervised monthly injections of lanreotide Autogel. All patients
(or partners) were successfully trained to administer unsupervised
injections. At the end of the study, 14 of the 15 patients met all criteria
for successful administration of unsupervised injections, which
suggests that unsupervised self- or partner depot injections are
a feasible treatment option for some patients with acromegaly. One
patient had fluctuating GH levels throughout the study and slightly
elevated mean GH levels on Study Completion compared with
Baseline. This patient had been on a 60-mg dose for only 4 months
before the start of the study, and erratic GH control may have been
due to suboptimal dosing rather than problems with lanreotide
Autogel administration. Both treatment groups had, overall, well-
maintained disease control, as assessed by the maintenance of GH
and IGF-1 levels. There was no loss of efficacy in patients who received
unsupervised injections compared with patients who continued to
receive injections from a healthcare professional. In addition, there
were no notable changes in serum lanreotide concentrations
throughout the study in either study group.
The injections were well tolerated by patients in both treatment
groups; there was no increase in the frequency or severity of pain
when patients moved to self- (or partner) injections from receiving
them from a healthcare professional. The small increase in reports
of redness and swelling in Test group patients was likely to reflect
the increased visibility of the injection site (thigh 
 
vs.
 
 buttock) rather
than a true increase in the frequency of redness and swelling.
There are a number of advantages to carrying out unsupervised
injections; for example, flexibility is increased as the patient can
receive their injections at home or away from home, for example,
on holiday or at work. In addition, the time spent travelling to and
attending a clinic for their treatment is greatly reduced. Lanreotide
Autogel also lends itself to self- or partner injection as it is supplied
in a ready-to-use syringe with a small injection volume. The fact that
lanreotide Autogel does not require reconstitution prior to injection
makes this preparation particularly suitable for self-administration.
The design of this study meant that patients were not randomized
to treatment; patients chose which method of treatment they were
willing to receive. This method will have inevitably introduced bias
and resulted in some differences in the baseline characteristics of the
groups. However, unsupervised injections would not appeal to all
patients, and therefore this reflects the choice that patients make in
a normal clinical setting. We found that the patients likely to consider
unsupervised injections are more likely to be the younger patients
of working age who were seeking to gain increased independence
from medical care. The 6-month duration of self-/partner injections
in this study was considered an appropriate length of time for
changes in GH and IGF-1 levels to be observed if the injections were
not being administered correctly.
This is the first study showing that lanreotide Autogel can be
successfully self- or partner administered in an unsupervised environ-
ment without affecting overall disease control. It also supports
Fig. 2 Individual GH and IGF-1 levels 
throughout the study. 
ULN, upper limit of normal.
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previous studies using lanreotide Autogel, confirming that it is an
effective and well-tolerated treatment.
 
1–7
 
 Although not specifically
assessed in this study, self- (or partner) injections reduce the number
of clinic appointments required by patients and therefore would be
expected to have cost benefits for healthcare providers.
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